Aurinia Pharmaceuticals Stock Price on August 22, 2024
AUPH Stock | USD 8.98 0.03 0.34% |
Below is the normalized historical share price chart for Aurinia Pharmaceuticals extending back to July 16, 2001. This chart has been adjusted for all splits and dividends and is plotted against all major global economic recessions. As of today, the current price of Aurinia Pharmaceuticals stands at 8.98, as last reported on the 27th of December, with the highest price reaching 9.01 and the lowest price hitting 8.90 during the day.
If you're considering investing in Aurinia Stock, it is important to understand the factors that can impact its price. Aurinia Pharmaceuticals appears to be somewhat reliable, given 3 months investment horizon. Aurinia Pharmaceuticals secures Sharpe Ratio (or Efficiency) of 0.12, which signifies that the company had a 0.12% return per unit of risk over the last 3 months. We have found twenty-nine technical indicators for Aurinia Pharmaceuticals, which you can use to evaluate the volatility of the firm. Please makes use of Aurinia Pharmaceuticals' Risk Adjusted Performance of 0.1202, mean deviation of 1.98, and Downside Deviation of 2.09 to double-check if our risk estimates are consistent with your expectations.
As of now, Aurinia Pharmaceuticals' Common Stock Total Equity is increasing as compared to previous years. The Aurinia Pharmaceuticals' current Common Stock is estimated to increase to about 1.3 B, while Other Stockholder Equity is projected to decrease to under 66.4 M. . As of now, Aurinia Pharmaceuticals' Price Fair Value is increasing as compared to previous years. Aurinia Stock price history is provided at the adjusted basis, taking into account all of the recent filings.
IPO Date 26th of January 1999 | 200 Day MA 6.4014 | 50 Day MA 8.3096 | Beta 1.456 |
Aurinia |
Sharpe Ratio = 0.1214
Best Portfolio | Best Equity | |||
Good Returns | ||||
Average Returns | ||||
Small Returns | AUPH | |||
Cash | Small Risk | Average Risk | High Risk | Huge Risk |
Negative Returns |
Estimated Market Risk
3.07 actual daily | 27 73% of assets are more volatile |
Expected Return
0.37 actual daily | 7 93% of assets have higher returns |
Risk-Adjusted Return
0.12 actual daily | 9 91% of assets perform better |
Based on monthly moving average Aurinia Pharmaceuticals is performing at about 9% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Aurinia Pharmaceuticals by adding it to a well-diversified portfolio.
Price Book 3.3138 | Enterprise Value Ebitda 233.4519 | Price Sales 5.8347 | Shares Float 128.9 M | Wall Street Target Price 10.8357 |
Related Headline
Viking Therapeutics Headline on 22nd of August 2024
Filed transaction by Viking Therapeutics Director, Officer President Ceo. Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3
Aurinia Pharmaceuticals Valuation on August 22, 2024
It is possible to determine the worth of Aurinia Pharmaceuticals on a given historical date. On August 22, 2024 Aurinia was worth 6.65 at the beginning of the trading date compared to the closed value of 6.65. We use multiple weighted factors in our valuation methodologies to arrive at the intrinsic value of Aurinia Pharmaceuticals stock. Still, in general, we apply an absolute valuation method to find Aurinia Pharmaceuticals' value based on its fundamental and technical indicators available within our service. As compared to an absolute model, our relative valuation model uses a comparative analysis of Aurinia Pharmaceuticals where we calculate exposure to its market risk and evaluate relevant financial multiples and ratios against Aurinia Pharmaceuticals' related companies.
Open | High | Low | Close | Volume | |
6.43 | 6.70 | 6.34 | 6.59 | 1,862,012 | |
08/22/2024 | 6.65 | 6.74 | 6.55 | 6.65 | 1,675,300 |
6.67 | 6.94 | 6.62 | 6.76 | 1,701,505 |
Backtest Aurinia Pharmaceuticals | | | Aurinia Pharmaceuticals History | | | Aurinia Pharmaceuticals Valuation | Previous | Next |
Aurinia Pharmaceuticals Trading Date Momentum on August 22, 2024
On August 23 2024 Aurinia Pharmaceuticals was traded for 6.76 at the closing time. The top price for the day was 6.94 and the lowest listed price was 6.62 . The trading volume for the day was 1.7 M. The trading history from August 23, 2024 was a factor to the next trading day price growth. The overall trading delta against the next closing price was 1.65% . The overall trading delta against the current closing price is 2.11% . |
Aurinia Pharmaceuticals Fundamentals Correlations and Trends
By evaluating Aurinia Pharmaceuticals' financials over time, investors can gain insight into future company performance. However, you can also analyze the published financial statements to find patterns among Aurinia Pharmaceuticals' main balance sheet or income statement drivers and many other relevant indicators that can statistically be found significantly correlated or uncorrelated. Aurinia financial account trend analysis is a perfect complement when working with valuation or volatility modules.About Aurinia Pharmaceuticals Stock history
Aurinia Pharmaceuticals investors dedicate a lot of time and effort to gaining insight into how a market's past behavior relates to its future. Access to timely market data for Aurinia is vital when making an investment decision, and regardless of whether you use fundamental or technical analysis, your return on investment in Aurinia Pharmaceuticals will depend on recognizing future opportunities and eliminating past mistakes. Historical data analysis is the study of market behavior over a given time. Recorded market-related data such as price, volatility, and volume can be quantified and studied over a defined period. Through a detailed examination of a market's past behavior, traders and investors can gain perspective on the inner workings of that market. The information obtained throughout analyzing Aurinia Pharmaceuticals stock prices may prove useful in developing a viable investing in Aurinia Pharmaceuticals
Last Reported | Projected for Next Year | ||
Common Stock Shares Outstanding | 143.2 M | 150.4 M | |
Net Loss | -97.4 M | -92.5 M |
Aurinia Pharmaceuticals Quarterly Net Working Capital |
|
Aurinia Pharmaceuticals Stock Technical Analysis
Aurinia Pharmaceuticals technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.
Price Boundaries
Aurinia Pharmaceuticals Period Price Range
Low | December 27, 2024
| High |
0.00 | 0.00 |
Aurinia Pharmaceuticals cannot be verified against its exchange. Please verify the symbol is currently traded on NASDAQ Exchange. If you still believe the symbol you are trying to look up is valid, please let us know, and we will check it as soon as possible.
Aurinia Pharmaceuticals December 27, 2024 Market Strength
Market strength indicators help investors to evaluate how Aurinia Pharmaceuticals stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading Aurinia Pharmaceuticals shares will generate the highest return on investment. By undertsting and applying Aurinia Pharmaceuticals stock market strength indicators, traders can identify Aurinia Pharmaceuticals entry and exit signals to maximize returns
Aurinia Pharmaceuticals Technical and Predictive Indicators
Predictive indicators are helping investors to find signals for Aurinia Pharmaceuticals' price direction in advance. Along with the technical and fundamental analysis of Aurinia Stock historical price patterns, it is also worthwhile for investors to track various predictive indicators of Aurinia to make sure they correctly time the market and exploit it's hidden potentials. Even though most predictive indicators are useful for the short-term horizon, it's virtually impossible to predict the unforeseen market. For traders with a short-term horizon, predictive indicators add value when properly applied. Long-term investors, however, may find many predictive indicators less useful.
Risk Adjusted Performance | 0.1202 | |||
Jensen Alpha | 0.4206 | |||
Total Risk Alpha | 0.2518 | |||
Sortino Ratio | 0.1776 | |||
Treynor Ratio | (3.03) |
Cycle Indicators | ||
Math Operators | ||
Math Transform | ||
Momentum Indicators | ||
Overlap Studies | ||
Pattern Recognition | ||
Price Transform | ||
Statistic Functions | ||
Volatility Indicators | ||
Volume Indicators |
Complementary Tools for Aurinia Stock analysis
When running Aurinia Pharmaceuticals' price analysis, check to measure Aurinia Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Aurinia Pharmaceuticals is operating at the current time. Most of Aurinia Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Aurinia Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Aurinia Pharmaceuticals' price. Additionally, you may evaluate how the addition of Aurinia Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
Commodity Directory Find actively traded commodities issued by global exchanges | |
Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments |